NasdaqGM:IOVABiotechs
Iovance Biotherapeutics (IOVA) Could Be 43% Undervalued After Record Q2 Results
Iovance Biotherapeutics (IOVA) is back in focus after reporting record second quarter revenue near US$100 million with a 56% margin, along with wider access to its TIL platform and an expanding solid tumor pipeline.
The strong quarterly update has arrived alongside a sharp rebound in Iovance Biotherapeutics’ share price, with a 7-day share price return of 19.19% and a 90-day move of 162.15%. This has contributed to a year-to-date share price return of 306.75% and a 1-year total shareholder...